Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell™ for Treatment of COPD

Rhea-AI Summary

Therapeutic Solutions International announced advancements in its COPD program alongside a pivotal COVID-19 clinical trial. New data reveals that combining JadiCell™ with Myeloid Derived Suppressor Cells enhances therapeutic efficacy, reducing lung damage and encouraging pulmonary regeneration. The FDA-cleared drug Leukine was also shown to boost Myeloid Derived Suppressor cell levels, improving JadiCell activity. The company has filed an Investigational New Drug application for JadiCells in COPD treatment and is exploring collaborations with immunotherapy stakeholders.

Positive

• Combination of JadiCells and Myeloid Derived Suppressor Cells shows superior efficacy in reducing lung damage.
• FDA-cleared drug Leukine enhances activity of JadiCells.
• Filed Investigational New Drug application for JadiCells in COPD treatment.
• Exploring potential collaborations in immunotherapy.

Negative

• None.

Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ through induction of a specific cell type called “Myeloid Derived Progenitor Cells”.

In a series of experiments, mice were treated with JadiCells, Myeloid Derived Suppressor Cells, and a combination of the two. It was found that the combination possessed superior ability to reduce lung damage and stimulate pulmonary regeneration. Additionally, administration of the FDA cleared drug Leukine was demonstrated to naturally increase levels of Myeloid Derived Suppressor cells and enhance activity of the JadiCells.

“As a medical doctor that routinely sees the devastation caused by COPD, I am extremely excited about the possibility of curing this disease” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “But in order to even begin talking about cures, we need to realize that a pathology as complex as COPD will not be cured by a 'magic bullet.' Therefore, we are always searching for new ways to continually increase the efficacy of our approaches.”

The Company recently filed an Investigational New Drug application for using its Phase III stem cells, called JadiCells, for treatment of COPD¹.

“These recent data are a result of our multidisciplinary approach to chronic diseases. Since there is an immunological mechanism at play here, we are currently in discussion with several immunotherapy stakeholders for collaborations and partnerships” said Timothy Dixon, President and CEO of the Company and co-inventor of the patent.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells

View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005565/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International